Literature DB >> 10689231

Neuropsychiatric problems in 2,500 long-term young travelers to the tropics.

I Potasman1, A Beny, H Seligmann.   

Abstract

BACKGROUND: The prevalence and features of travel associated neuropsychiatric problems (NPP) and their relation to previous psychological consultations, antimalarials and recreational drug use have not been adequately studied.
METHODS: A two-phase postal and telephone survey has been conducted among 2,500 young travelers to tropical countries. We measured the rate and duration of NPP, characterized their features, and their association with previous psychological profiles, itinerary, type of travel, consumption of recreational drugs, and malaria prophylaxis.
RESULTS: First phase: Out of 1,340 respondents, 151 (11.3%) indicated that they had NPP during travel, in contrast with 2.3% who needed psychological consultation before travel (p<.001). Second phase: 117 of 151 responded to the study questionnaire. The mean age of the respondents was 24.4 years, 54.7% were female, and the mean stay abroad was 5.3 months. The most common NPP were sleeping disturbances (52.1%), fatigue (48.7%) and dizziness (39.3%). Thirty-three travelers (2.5%) had severe symptoms, and 16 (1.2%) had symptoms lasting more than 2 months. Seven travelers had pure or mixed depressive symptoms. Consumption of recreational drugs was admitted by 22.2%. Mefloquine was used significantly more often by those who suffered NPP, than by the entire cohort (98.2% vs. 70.7%; p<.001).
CONCLUSIONS: Long-term travel to the tropics was associated, in this cohort, with a considerable rate of neuropsychiatric symptoms. The majority of the responding travelers were females, used mefloquine as prophylaxis, and at least one fifth used recreational drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689231     DOI: 10.2310/7060.2000.00002

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  11 in total

1.  Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

2.  The most vulnerable travelers: patients with mental disorders.

Authors:  Péter Felkai; Tamás Kurimay
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

Review 3.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials.

Authors:  Christoph R Meier; Karen Wilcock; Susan S Jick
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Reversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis.

Authors:  G O Adjei; V M Adabayeri; S H Annobil
Journal:  Ghana Med J       Date:  2012-09

Review 6.  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers.

Authors:  A M J Croft; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 7.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

8.  Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

Authors:  Ashley M Croft; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2002-03-25       Impact factor: 3.295

9.  Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.

Authors:  Mary A Bitta; Symon M Kariuki; Clifford Mwita; Samson Gwer; Leah Mwai; Charles R J C Newton
Journal:  Wellcome Open Res       Date:  2017-06-02

10.  Illness in long-term travelers visiting GeoSentinel clinics.

Authors:  Lin H Chen; Mary E Wilson; Xiaohong Davis; Louis Loutan; Eli Schwartz; Jay Keystone; Devon Hale; Poh Lian Lim; Anne McCarthy; Effrossyni Gkrania-Klotsas; Patricia Schlagenhauf
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.